MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) are currently the most effective treatment for non-small cell lung cancer (NSCLC) patients, who carry primary EGFR mutations. However, the patients eventually develop drug resistance to EGFR-TKIs after approximately one year. In addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chao-Ju, Liu, Yu-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915726/
https://www.ncbi.nlm.nih.gov/pubmed/33562150
http://dx.doi.org/10.3390/ph14020130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915726/
https://www.ncbi.nlm.nih.gov/pubmed/33562150
http://dx.doi.org/10.3390/ph14020130

Ejemplares similares